insights

COVID-19 Vaccine Updates and Latest Information

Updated: 10/8/2021

Throughout 2021, The Institute for Functional Medicine has presented a series of webinars updating practitioners about the latest medical research on mitigating SARS-CoV-2 infection and addressing post-acute sequelae of SARS-CoV-2 (PASC). These feature members of IFM’s COVID-19 task force and guest subject matter experts addressing the latest updates and answering audience questions. The recordings of all of these webinars are available below.

IFM has also released a free online resource called Key Clinical Takeaways for Mitigating SARS-CoV-2 Infection. This online learning module discusses viral mechanisms of SARS-CoV-2 infection and offers key clinical considerations and therapeutic interventions to patients at various clinical stages of infection, including pre-exposure, post-exposure without symptoms, and post-exposure with symptoms. It details the specific interventions that you can put into practice right now at this stage of the pandemic to mitigate this risk for all of your patients. Vaccines are helpful in decreasing the severity of illness and the recommendations are helpful for both vaccinated and unvaccinated patients.

Key Clinical Takeaways for Mitigating SARS-CoV-2 Infection

December 2021

Show Prior Webinars +

Vaccine Information

As discussed by the panelists, in order to properly assess each vaccine, IFM has created this informational dashboard for each approved vaccine, as well as those in phase 3 clinical trials. We continue to monitor outcomes data for each vaccine after its initial release and will update this dashboard accordingly.

Click on table to zoom

References

  1. US Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. Revised October 29, 2021. Accessed November 5, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-va­ccine
  2. Centers for Disease Control and Prevention. CDC recommends pediatric COVID-19 vaccine for children 5 to 11 years. Published November 2, 2021. Accessed November 5, 2021. https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html
  3. Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. Updated December 6, 2021. Accessed December  6, 2021. https://covid.cdc.gov/covid-data-tracker/#vaccinations
  4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  5. Jenco M. AAP, CDC recommend COVID-19 vaccine for ages 12 and older. AAP News and Journals. Published May 12, 2021. Accessed May 13, 2021. https://www.aappublications.org/news/2021/05/12/cdc-aap-pfizer-covid-vaccine-teens-051221
  6. Perez JL. COVID-19 vaccine BNT162b2: safety, immunogenicity, and efficacy in subjects 12-15 years-old. Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/02-COVID-Perez-508.pdf
  7.  US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised October 20, 2021. Accessed November 5, 2021. https://www.fda.gov/media/144637/download
  8. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA takes additional actions on the use of a booster dose for COVID-19 vaccines. Published October 20, 2021. Accessed November 5, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines
  9. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
  10. US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee meeting February 26, 2021: FDA briefing document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Revised February 26, 2021. Accessed February 28, 2021. https://www.fda.gov/media/146217/download
  11. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
  12. Medicines & Healthcare Products Regulatory Agency. Decision: summary of product characteristics for Vaxzevria. Updated October 21, 2021. Accessed November 5, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca
  13. European Medicines Agency. EMA recommends COVID-19 vaccine AstraZeneca for authorisation in the EU. Updated January 29, 2021. Accessed March 12, 2021. https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu#:~:text=COVID%2D19%20Vaccine%20AstraZeneca%20is,Commission%20on%2029%20January%202021.&text=This%20is%20the%20third%20COVID,EMA%20has%20recommended%20for%20authorisation
  14. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet. 2021; 397(10269):98]. Lancet. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1
  15. Graham F. Daily briefing: first authorization for Novavax COVID vaccine. Nature. Published November 3, 2021. Accessed November 5, 2021. https://www.nature.com/articles/d41586-021-03048-7
  16. Novavax. Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial. Published June 14, 2021. Accessed June 16, 2021. https://ir.novavax.com/2021-06-14-Novavax-COVID-19-Vaccine-Demonstrates-90-Overall-Efficacy-and-100-Protection-Against-Moderate-and-Severe-Disease-in-PREVENT-19-Phase-3-Trial
  17. World Health Organization. Tracking SARS-CoV-2 variants. Updated November 26, 2021. Accessed December 6, 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  18. Mahase E. COVID-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ. 2020;371:m4826. doi:10.1136/bmj.m4826
  19. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7
  20. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
  21.  Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790-792. doi:10.1038/s41591-021-01316-7
  22. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine. Nat Commun. 2021;12(1):6379. doi:10.1038/s41467-021-26672-3
  23. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. Published online October 27, 2021. doi:10.1056/NEJMoa2114228
  24. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant – National Healthcare Safety Network, March 1 – August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-1166. doi:10.15585/mmwr.mm7034e3
  25. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status – New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1150-1155. doi:10.15585/mmwr.mm7034e1
  26. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. Published online September 1, 2021. doi:10.1016/S1473-3099(21)00460-6
  27. Oliver S. EtR framework: Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years. Centers for Disease Control and Prevention. Updated November 4, 2021. Accessed November 5, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/08-COVID-Oliver-508.pdf
  28. Pfizer. Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Published April 1, 2021, Accessed April 15, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
  29. Centers for Disease Control and Prevention. Science brief: COVID-19 vaccines and vaccination. Updated September 15, 2021. Accessed November 5, 2021. https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated-people.html#ref29
  30. Parry HM, Tut G, Faustini S, et al. BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralization of P.1 Brazilian variant. Updated March 31, 2021. Accessed April 15, 2021. doi:10.2139/ssrn.3816840
  31. Liu Y, Liu J, Xia H, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021;385(5)472-474. doi:10.1056/NEJMc2106083
  32. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273-275. doi:10.1038/s41586-021-03693-y
  33. Centers for Disease Control and Prevention. Delta variant: what we know about the science. Updated August 26, 2021. Accessed Sept 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
  34. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891
  35. Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med. 2021;385(14):1330-1332. doi:10.1056/NEJMc2112981
  36. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. Published online October 14, 2021. doi:10.1038/s41591-021-01548-710.1038/s41591-021-01548-7
  37. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint. medRxiv. Published October 6, 2021. doi:10.1101/2021.09.15.21263583
  38.  Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385:1393-1400. doi:10.1056/NEJMoa2114255
  39. Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385:1627-1629. doi:10.1056/NEJMc2113468
  40. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093-2100. doi:10.1016/S0140-6736(21)02249-2
  41. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial [published online December 2, 2021]. Lancet. doi:10.1016/S0140-6736(21)02717-3
  42. Centers for Disease Control and Prevention. The Vaccine Adverse Reporting System (VAERS) results. Accessed February 12, 2021. https://wonder.cdc.gov/vaers.html
  43. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51. doi.10.15585/mmwr.mm7002e1
  44. Tamaki A, Cabrera CI, Li S, et al. Incidence of Bell palsy in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(8):767-768. doi:10.1001/jamaoto.2021.1266
  45. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science. Published June 1, 2021. Accessed September 8, 2021. https://www.science.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination
  46. Thompson MG, Burgess JL, Naleway Al, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV2 infection among health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
  47. Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384(15):1468-1470. doi:10.1056/NEJMc2102179
  48. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. doi:10.15585/mmwr.mm7004e1
  49. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384(19):1824-1835. doi:10.1056/NEJMoa2034201
  50. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964-1965. doi:10.1056/NEJMc2105869
  51. American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). Updated August 12, 2021. Accessed September 9, 2021. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  52. Shimabukuro T; CDC COVID-19 Vaccine Task Force. Update: thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. Advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf
  53. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
  54. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. doi:10.1016/S0140-6736(20)32623-4
  55. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840
  56. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Updated April 7, 2021. Accessed April 15, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
  57. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899-1909. doi:10.1056/NEJMoa2103055